Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The plugged honeycomb structure includes a plurality of honeycomb segments, a bonding layer, and plugging portions which plug open ends of cells of each honeycomb segment, and in the honeycomb segment, at least two types of cells having different sectional shapes are formed to constitute predetermined repeated arrangement patterns, and in rim circumferential wall cells including rims of the cells surrounded with partition walls and segment circumferential walls, an inflow open area of each corner rim circumferential wall cell disposed in each corner portion of the honeycomb segment is 1.1 times or more as large as an average inflow open area of non-corner rim circumferential wall cells arranged in portions other than the corner portions, or an outflow open area of the corner rim circumferential wall cell is 1.1 times or more as large as an average outflow open area of the non-corner rim circumferential wall cells.

Abstract: The plugged honeycomb structure includes a plurality of honeycomb segments, a bonding layer, and plugging portions which plug open ends of cells of each honeycomb segment, and in the honeycomb segment, at least two types of cells having different sectional shapes are formed to constitute predetermined repeated arrangement patterns, and a ratio of a value R2s obtained by dividing an average sectional area S2in of inflow cells by an average sectional area S2out of outflow cells in a partial rim circumferential wall cell region is in a range of 1.7 times or more and 2.0 times or less to a value R1s obtained by dividing an average sectional area S1in of the inflow cells by an average sectional area S1out of the outflow cells in a whole rim partition wall cell region.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A honeycomb structure has a plurality of pillar honeycomb segments with a porous partition wall that defines a plurality of cells extending from an inflow end face as one end face to an outflow end face as another end face and becoming channels for a fluid and a bonding layer that bonds side surfaces of the plurality of honeycomb segments one another, the bonding layer contains a plurality of plate-shaped particles, the plate-shaped particles are laminated in a thickness direction X of the bonding layer at a cross section of the bonding layer cut off to the thickness direction of the bonding layer, the number of particles ? meets Expression: number of particles ?>10, and the number of particles ? and the number of particles ? meet a relationship of Expression: (number of particles ?/number of particles ?)>3.

Abstract: A honeycomb structure has a pillar-shaped honeycomb structure body having porous partition walls which defines cells which forms a passage of liquid extended from an inflow end face toward an outflow end face, a circumferential wall arranged to surround a circumference of the partition walls. The honeycomb structure body has an outermost circumference cell structure including a complete cell arranged at the outermost circumference of the honeycomb structure body, a center cell structure formed by the cells arranged at a center part at an inner side to the outermost circumference cell structure, and a boundary wall arranged at a boundary part between the outermost circumference cell structure and the center cell structure. The outermost circumference cell structure and the center cell structure are formed as different structures to each other, and a thickness of the boundary wall is set to be thicker than a thickness of the circumferential wall.

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra?, Rc, Rf, X2, Rd, Rd?, Re, Re?, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

Abstract: There is provided a honeycomb structure where a crack at honeycomb segments, which constitute a honeycomb bonded assembly, is reduced. A honeycomb structure has a pillar-shaped honeycomb bonded assembly that has a plurality of pillar-shaped honeycomb segments having a porous partition wall defining a plurality of cells extending from an inflow end face as one end face to an outflow end face as another end face and becoming channels for a fluid, and a bonding layer bonding side surfaces of the plurality of honeycomb segments, and in the honeycomb bonded assembly, at 25 to 800° C., a thermal expansion coefficient of the bonding layer is larger than a thermal expansion coefficient of the honeycomb segment.

Abstract: There is provided a honeycomb structure where a crack at a honeycomb substrate is reduced. A honeycomb structure has a honeycomb substrate that has a porous partition wall defining a plurality of cells extending from an inflow end face as one end face to an outflow end face as another end face and becoming channels for a fluid, and an outer circumference coating layer disposed at an outer circumference of the honeycomb substrate. At 25 to 800° C., a thermal expansion coefficient of the outer circumference coating layer is larger than a thermal expansion coefficient of the honeycomb substrate. The thermal expansion coefficients of the outer circumference coating layer and the thermal expansion coefficient at 25 to 800° C. preferably meet a relationship represented by the expression: 1.1<(the thermal expansion coefficient of the outer circumference coating layer/the thermal expansion coefficient of the honeycomb substrate)<40.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: In an image forming apparatus including an apparatus body, an image forming portion, a conveyance unit, a storage portion, a sheet movement unit, a memory portion, and a control portion, in a case where an image forming instruction to perform image formation on a sheet has been received, the control portion provides notification of a plurality of discharging methods of storing the sheet which is an object of the image forming instruction, into the storage portion and then exposing the sheet outside of the apparatus body via an opening of the storage portion, based on first information stored in the memory portion and second information about the sheet which is an object of the image forming instruction, and controls the conveyance unit and the sheet movement unit based on a discharging method selected from among the plurality of discharging methods.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: An endoscope system includes an endoscope including an image pickup section that picks up an image of a subject lumen organ, a recording section that records three-dimensional image information of a lumen organ acquired from a medical diagnosis apparatus, a position estimating section that estimates a distal end position of the endoscope, a lumen-diameter acquiring section that acquires a lumen diameter of the organ in the estimated position of the distal end, a condition determining section that determines whether the acquired lumen diameter is smaller than the reference lumen diameter, an image-change-amount detecting section that detects a change amount of a predetermined parameter in an endoscopic image picked up by the image pickup section, a virtual-endoscopic-image generating section that generates a virtual endoscopic image from any visual point position, and an information recording section that records a position of a distal end of an insertion section and the virtual endoscopic image.

Abstract: Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra?, Rc, Rf, X2, Rd, Rd?, Re, Re?2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.